Ketamine vs Psilocybin Therapy: Which Is Right for You?

Q: Is psilocybin legal for depression treatment?

As of early 2026, psilocybin remains a Schedule I controlled substance under federal law in the United States. Oregon has implemented a regulated psilocybin services program, and some cities have decriminalized possession. However, psilocybin is not FDA-approved for any psychiatric condition. Ketamine, by contrast, is a Schedule III medication that can be legally prescribed off-label by licensed physicians in all 50 states.

Q: Is ketamine or psilocybin more effective for depression?

Both substances have shown promising results in clinical research for depression, but they are difficult to compare directly. Ketamine has a larger body of clinical evidence and is more widely available. Psilocybin research, while encouraging, is still in earlier stages with fewer completed large-scale trials. Head-to-head comparisons are limited, and individual responses may vary significantly.

Q: Can I access psilocybin therapy now?

Access to legal psilocybin therapy is currently very limited in the United States. Oregon's regulated program is operational but only available at licensed service centers within the state. FDA-approved psilocybin therapy is not yet available. Ketamine therapy, including at-home oral ketamine through providers like Isha Health, is legally accessible in many states today.

Q: Do ketamine and psilocybin work through the same mechanism?

No. Ketamine primarily acts on NMDA glutamate receptors and may promote rapid synaptogenesis. Psilocybin primarily acts on serotonin 5-HT2A receptors and produces its effects through a different pathway. Both may promote neuroplasticity, but through distinct neurochemical mechanisms.

Interest in psychedelic-assisted therapy for depression and other mental health conditions has grown significantly. Both ketamine and psilocybin have shown promise in clinical research, but they differ in critical ways, including legal status, accessibility, mechanisms of action, and the maturity of their evidence base. Here is a straightforward comparison to help you understand your options.

Comparison at a glance

Factor	Ketamine	Psilocybin
How it works	NMDA receptor antagonism; modulates glutamate signaling and may promote synaptogenesis	Serotonin 5-HT2A receptor agonism; may promote neuroplasticity and altered states of consciousness
Speed of relief	Some patients report improvement within hours to days	Some trials have reported improvement within 1-4 weeks; research is ongoing
Administration	Oral/sublingual (at home), IV, or intranasal; sessions last 1-2 hours	In supervised clinical setting; sessions last 6-8 hours with preparation and integration sessions
Cost	At-home oral: ~$350/appointment + $50-150/mo medication	Oregon program: $1,500-3,500+ per session (includes facilitator fees); clinical trials: no cost
FDA status	FDA-approved as an anesthetic; used off-label for depression. Esketamine (Spravato) is FDA-approved for TRD.	Schedule I controlled substance; not FDA-approved for any psychiatric indication. FDA breakthrough therapy designation granted for research.
Side effects	Dissociation, nausea, dizziness, elevated blood pressure (transient)	Anxiety, nausea, headache, challenging psychological experiences, perceptual changes lasting hours
Evidence level	Substantial and growing clinical evidence; widely used in clinical practice	Promising early-phase clinical trials; larger confirmatory trials still underway or recently completed

Key differences

Legal access: This is the most practical distinction. Ketamine is a Schedule III medication that can be legally prescribed off-label by any licensed physician in the United States. Psilocybin remains a Schedule I substance under federal law and is only available through Oregon's regulated services program or clinical research trials. This means ketamine is currently accessible to far more patients across the country.

Session experience: Ketamine sessions, particularly with oral or sublingual forms, typically last 1-2 hours and involve a dissociative experience that many patients describe as manageable. Psilocybin sessions are significantly longer (6-8 hours) and involve more intense perceptual and psychological experiences that require extensive preparation and integration with trained facilitators.

Treatment model: Ketamine therapy can be administered at home through telehealth programs like Isha Health, with ongoing physician supervision. Psilocybin therapy in Oregon requires in-person attendance at a licensed service center with a trained facilitator present for the entire session, making it a more intensive time commitment.

Maturity of evidence: While both have shown promising results, ketamine has a substantially larger evidence base, including multiple meta-analyses and large retrospective studies. Psilocybin research is encouraging but is still in relatively earlier stages. The FDA has granted psilocybin breakthrough therapy designation, signaling its potential, but approval has not yet been granted.

When to consider ketamine

You want a legally accessible treatment available now, not dependent on your state or a clinical trial
You prefer the convenience of at-home treatment with telemedicine support
You want a treatment with an established and growing evidence base
You prefer shorter sessions (1-2 hours vs. 6-8 hours)

When to consider psilocybin

You are in Oregon and can access a licensed psilocybin service center
You are interested in enrolling in a clinical trial studying psilocybin for depression
You are specifically seeking a serotonergic psychedelic experience with extensive facilitation
You have tried ketamine and other treatments without adequate relief

Frequently asked questions

Is psilocybin legal for depression treatment?

Psilocybin remains a Schedule I controlled substance under federal law. Oregon has a regulated program, and some cities have decriminalized possession. It is not FDA-approved for any psychiatric condition. Ketamine can be legally prescribed off-label in all 50 states.

Is ketamine or psilocybin more effective for depression?

Both show promising results, but direct comparisons are limited. Ketamine has a larger evidence base and is more widely available. Individual responses vary, and more research is needed to understand how they compare for different patient populations.

Can I access psilocybin therapy now?

Legal access is very limited. Oregon's program is operational at licensed service centers. FDA-approved psilocybin therapy is not yet available. At-home ketamine through Isha Health is accessible in Oregon and many other states today.

Do ketamine and psilocybin work through the same mechanism?

No. Ketamine primarily acts on NMDA glutamate receptors while psilocybin acts on serotonin 5-HT2A receptors. Both may promote neuroplasticity but through distinct pathways.

Ready to explore a treatment available now?

Ketamine therapy is legally accessible today. Talk to one of our physicians.

Check Appointment Availability